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Background
Pancreatic adenocarcinoma remains a notoriously lethal 
malignancy, currently ranking as the fourth leading cause 
of cancer related death in the US, despite a relatively low 
incidence (1). Until recently, gemcitabine and erlotinib 
were the only agents known to improve overall survival 
(OS) in patients with unresectable pancreatic cancer 
to approximately 6 to 7 months (2). In 2011, a non-
gemcitabine based therapy, FOLFIRINOX, was shown 
to improve survival to 11 months when compared with 
gemcitabine in a phase III randomized clinical trial in 
the first line setting (3). After failure of first line therapy, 
however, the options continue to be even more limited. 
There are currently no widely accepted treatments beyond 
first line. The only regimen to show evidence of survival 
benefit in a context of a randomized trial in this setting is 
oxaliplatin/5-FU/leucovorin (OFF), which improved overall 
survival to 4.8 months from 2.3 months with best supportive 
care (4). 
Nab-paclitaxel (trade name, Abraxane), is paclitaxel 
bound to nano-particle albumin, a first drug of this 
type. Nab-paclitaxel was initially developed to avoid 
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hypersensitivity reactions that resulted from solvents 
such as cremephor that are used to dissolve paclitaxel. 
Nab-paclitaxel has been approved by the Food and Drug 
Administration since 2004 for use in metastatic breast 
cancer as well as metastatic non-small cell lung cancer 
(5,6). In addition to eliminating hypersensitivity reaction, 
it has also been postulated that uptake of albumin by tumor 
cells may allow improved intra-tumoral delivery of nab-
paclitaxel. This may be especially relevant in pancreatic 
cancer given the dense stromal component of this 
malignancy that has been postulated as being central to its 
chemoresistance (7). In fact, a protein present in stroma 
of many pancreatic adenocarcinomas, secreted protein 
acidic and rich in cysteine (SPARC), may help serve as an 
albumin-binding protein that sequesters nab-paclitaxel to 
concentrate the drug intratumorally (8).
Nab-paclitaxel was first used in pancreatic cancer 
two years ago in combination with gemcitabine in the setting 
of a phase I-II study, where it was found to be tolerable 
with substantial activity (9). The results of a phase III trial 
comparing gemcitabine to gemcitabine combined with nab-
paclitaxel were recently presented in abstract form showing 
improved survival of two months from 6.7 to 8.5 months 
with the combination therapy in previously untreated 
patients with advanced pancreatic cancer (10). In the second 
line setting, a small phase II study has also shown evidence 
of activity of nab-paclitaxel monotherapy in patients who 
have progressed through gemcitabine (11). This study 
involved 19 patients and showed an overall survival of 
7.3 months. 36.8% of patients had stable or partial response 
on best imaging in this study. No other data is available, 
to the best of our knowledge, however, on the use of nab-
paclitaxel monotherapy in refractory pancreatic cancer, 
which is an area of dire need. Here, we report the results of 
a retrospective and prospective registry study documenting 
our experience with nab-paclitaxel monotherapy in heavily 




Patients with pancreatic adenocarcinoma at Washington 
University in St. Louis Siteman Cancer Center, who 
were treated with nab-paclitaxel monotherapy between 
January 2009 and July 2012, were eligible for inclusion. 
A retrospective and prospective registry was established 
to capture all patients after Institutional Board Review 
(IRB) approval was obtained. Patients were 18 years of 
age or older and had pathologically confirmed pancreatic 
adenocarcinoma. All patients had advanced or recurrent 
pancreatic cancer which had progressed through at least one 
earlier line of chemotherapy. Demographic data collected 
included age, race, gender, ECOG performance status, and 
prior treatments. Baseline laboratory values were recorded 
including tumor marker CA 19-9. Data collection was 
stopped in September 2012. All patients treated with at least 
one dose of nab-paclitaxel were included for analysis. 
Treatment and monitoring 
Nab-paclitaxel dosing and schedule (every week for 
two weeks then one week off versus every week for 
three weeks then one week off) was chosen by the practicing 
oncologist. The dose and schedule used was recorded for 
the purposes of this study. Staging imaging (CT or MRI) 
was obtained per the discretion of the treating oncologists 
during treatment. When available after at least one month 
of therapy, the images were analyzed according to the 
Response Evaluation Criteria in Solid Tumors. Clinic notes 
were also reviewed for clinician assessment of response 
and if it differed from radiological assessment, the clinical 
assessment of response was to be used. 
All clinic notes were reviewed for any hospitalizations, 
dose reductions or cessation of treatment due to adverse 
events. Laboratory values before and after each treatment 
cycle were also reviewed to corroborate and document any 
additional adverse events using complete blood count and 
comprehensive metabolic panel in each patient. Adverse 
events were graded using National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(version 4.0). Patients who received at least one dose of 
chemotherapy were included for toxicity evaluation. 
Statistical analysis 
Data analysis for this study was descriptive in nature. 
Demographic and clinical characteristics, as well as 
adverse events and follow-up time were summarized using 
means, medians, counts and frequencies as appropriate. 
Progression-free survival (PFS) was defined as time of 
nab-paclitaxel initiation to time of progression based on 
imaging/clinical evaluation, or time of death, whichever 
occurred first. Those patients alive and progression-free 
were censored on September 1, 2012. OS was defined as 
time of nab-paclitaxel initiation to time of death. When not 
noted in clinical records, the Social Security Death index 
was used to ascertain survival
Results
Patients
A total of 20 patients were registered for this study. Four 
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of the 20 had already finished treatment at the start of this 
registry and were reviewed retrospectively. The rest were 
reviewed either completely prospectively or prospectively 
and retrospectively as appropriate (5 and 11 patients 
respectively). Patient characteristics are listed in Table 1. 
Median age of patients was 63.5, with a wide range of 45 to 
84 years old. There were equal number of men and women 
and majority had an ECOG of 0 or 1 (90%). All patients 
had previously received gemcitabine monotherapy and some 
had progressed through other additional chemotherapies, 
including FOLFIRINOX in 8 patients and nab-paclitaxel 
combined with other agents in 3 patients. Median 
number of prior lines of therapy was 2, with a range of 
1 to 4. Overall, 18 patients (90%) had received at least two 
prior treatment regimens.
Treatment
Patients received treatment for a median of 15 weeks, ranging 
from one to six cycles. Eleven patients (55%) were able to 
receive therapy for at least 4 months. Patients were started 
on nab-paclitaxel at 100 or 125 mg/m2, with three patients 
having doses later decreased to 75 or 80 mg/m2. Roughly 
half the patients were treated on a three week on, one week 
off cycle, while the other half were treated on a two week on, 
one week off cycle. Median dose was 100 mg/m2. 
Majority of patients discontinued treatment due to 
either progression of disease or decline in functional status 
(15 patients, 75%). Three patients (15%) were still on nab-
paclitaxel at the time of closing study data collection. 
Clinical outcome
Best response imaging was available in 17 patients (Table 2). 
Table 1 Baseline patient characteristics
Patient characteristics





Male 10 (50%) 
Female 10 (50%) 




Nab-Paclitaxel combination regimens 3 (15%)
Table 2 Best response by RECIST criteria in 17 patients with 
available imaging after at least one month of therapy
Response
Number of patients with response/ 
evaluable number of patients (%)
Partial or complete response 0/17
Stable disease 11/17 (64.7%)
Disease progression 6/17 (35.3%)
50% decline in CA 19-9 7/12 (58.3%)
Last row shows number/percentage of patients with a baseline 
elevated CA 19-9 level, who had a 50% or more decline in CA 
19-9 levels after therapy
Of these patients, while no patient had a complete or partial 
response, 65% had stable disease at as their best response 
on imaging. 35% progressed without any stabilization of 
disease. There was no discrepancy between response by 
imaging and clinical impression. Of the 12 patients who had 
elevated baseline CA 19-9, seven (58%), had a 50% or more 
decline in levels. The three patients who had uninterrupted 
CA 19-9 elevation post therapy were all shown to have 
progressive disease on first imaging. 
Median progression free survival was 3.7 months. In 
patients who had a response, median duration of response 
was 4.7 months. At the end of data collection, 6 out of 
19 patients were still living. Median overall survival in the 
study population was 5.2 months. 
Adverse events
Adverse events directly attributed to nab-paclitaxel were 
the cause of treatment discontinuation in only two patients 
(10%), both being mucositis, in one concurrently with 
neutropenia. Grade 2 or worse fatigue was seen in four 
patients while significant dehydration was seen in one 
patient (grade 3). Only one patient was hospitalized as a 
result of therapy. Three patients (15%) developed grade 
3 or 4 neutropenia with one also developing neutropenic 
fever. An unexpected adverse event possibly related to nab-
paclitaxel was pneumonitis that occurred in five patients. All 
cases of pneumonitis were grade 1.
Discussion
Advanced pancreatic cancer has recently witnessed the 
introduction of the first regimens to improve on gemcitabine 
therapy in decades. Two years ago, FOLFIRINOX, a 
combination regimen consisting of 5-FU, oxaliplatin and 
irinotecan was shown in a landmark study to improve survival 
compared with gemcitabine from 6.8 to 11.1 months (3). 
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Earlier this year, combination of gemcitabine with nab-
paclitaxel was also shown to improve survival compared with 
gemcitabine, albeit more modestly from 6.7 to 8.5 months (10). 
Although these developments are cause for hope in a field 
which has seen little to be excited about in a long time, 
they clearly represent modest progress. Patients eventually 
progress through these regimens and there is a dire need for 
treatment options beyond first line of therapy.
Here we present a registry study examining nab-
paclitaxel monotherapy beyond first line of therapy. 90% 
of patients included in our study had received at least 
two other lines of therapy, including nab-paclitaxel 
combination therapy and/or FOLFIRINOX in some. We 
found nab-paclitaxel therapy to be relatively well tolerated 
in this pretreated patient population with good level of 
clinical activity. The PFS was 3.7 months and OS was 
5.2 months, with more than 4 months duration of response 
in patients who had stabilization of disease. Responses in 
CA 19-9 were seen along with imaging response. 
Our study has the usual limitations of being a non 
randomized study. Nab-paclitaxel dosage schedule and dose 
reductions in response to toxicity were at the discretion of 
the treating oncologist thereby limiting recommendations 
on a dose schedule. Despite these limitations and the small 
number of patients, however, our results are consistent with 
evidence of benefit from nab-paclitaxel monotherapy seen 
in another small study (11). Furthermore, our study is the 
first to our knowledge to include patients treated with either 
nab-paclitaxel combination therapy or FOLFIRINOX. 
This is significant given that either of these two regimens 
is now considered a standard treatment option for first line 
therapy of patients with advanced pancreatic cancer. Our 
study represents evidence that nab-paclitaxel monotherapy 
could be an option in these patients upon progression.
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